These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 9543435)
21. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422 [TBL] [Abstract][Full Text] [Related]
22. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230 [TBL] [Abstract][Full Text] [Related]
23. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411 [TBL] [Abstract][Full Text] [Related]
24. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. Menon V; Ayala VI; Rangaswamy SP; Kalisz I; Whitney S; Galmin L; Ashraf A; LaBranche C; Montefiori D; Petrovsky N; Kalyanaraman VS; Pal R J Gen Virol; 2017 Aug; 98(8):2143-2155. PubMed ID: 28758637 [TBL] [Abstract][Full Text] [Related]
25. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P). Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906 [TBL] [Abstract][Full Text] [Related]
26. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
27. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251. Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249 [TBL] [Abstract][Full Text] [Related]
28. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the immune response and protective effects of rhesus macaques vaccinated with biodegradable nanoparticles carrying gp120 of human immunodeficiency virus. Himeno A; Akagi T; Uto T; Wang X; Baba M; Ibuki K; Matsuyama M; Horiike M; Igarashi T; Miura T; Akashi M Vaccine; 2010 Jul; 28(32):5377-85. PubMed ID: 20472029 [TBL] [Abstract][Full Text] [Related]
38. Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time. Silverstein PS; Mackay GA; Mukherjee S; Li Z; Piatak M; Lifson JD; Narayan O; Kumar A J Virol; 2000 Nov; 74(22):10489-97. PubMed ID: 11044093 [TBL] [Abstract][Full Text] [Related]
39. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Heeney J; Akerblom L; Barnett S; Bogers W; Davis D; Fuller D; Koopman G; Lehner T; Mooij P; Morein B; de Giuli Morghen C; Rosenwirth B; Verschoor E; Wagner R; Wolf H Immunol Lett; 1999 Mar; 66(1-3):189-95. PubMed ID: 10203054 [TBL] [Abstract][Full Text] [Related]
40. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. Voss G; Manson K; Montefiori D; Watkins DI; Heeney J; Wyand M; Cohen J; Bruck C J Virol; 2003 Jan; 77(2):1049-58. PubMed ID: 12502820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]